Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients
- PMID: 2021551
- PMCID: PMC1972343
- DOI: 10.1038/bjc.1991.147
Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients
Abstract
We determined the amount of tamoxifen, N-desmethyltamoxifen (metabolite X), N-desdimethyltamoxifen (metabolite Z), and hydroxylated metabolites (Y, B, BX) in brain metastases from breast cancer and in the surrounding brain tissues. Specimens were collected from the breast cancer patients who received tamoxifen for 7-180 days and with the last dose taken within 28 h before surgical removal of the tumour. The concentrations of tamoxifen and its metabolites were up to 46-fold higher in the brain metastatic tumour and brain tissue than in serum. Metabolite X was the most abundant species followed by tamoxifen and metabolite Z. Small but significant amounts of the hydroxylated metabolites, trans-1(4-beta-hydroxyethoxyphenyl)-1,2-diphenylbut-1-ene (metabolite Y), 4-hydroxytamoxifen (metabolite B) and 4-hydroxy-N-desmethyltamoxifen (metabolite BX) were detected in most specimens. The ratios between the concentrations of tamoxifen and various metabolites were similar in tumour, brain and serum. This is the first report on the distribution of tamoxifen and metabolites into human brain and brain tumour, and the data form a basis for further investigation into the therapeutic effects of tamoxifen on brain metastases from breast cancer.
Similar articles
-
Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.Cancer Res. 1989 Apr 15;49(8):2175-83. Cancer Res. 1989. PMID: 2702659
-
Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment.Cancer Res. 1991 Sep 15;51(18):4837-44. Cancer Res. 1991. PMID: 1893376
-
Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer.Cancer Res. 1983 Mar;43(3):1446-50. Cancer Res. 1983. PMID: 6825112
-
Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts.Eur J Cancer Clin Oncol. 1989 Dec;25(12):1769-76. doi: 10.1016/0277-5379(89)90347-7. Eur J Cancer Clin Oncol. 1989. PMID: 2632258
-
Excretion of hydroxylated metabolites of tamoxifen in human bile and urine.Anticancer Res. 2005 Nov-Dec;25(6C):4487-92. Anticancer Res. 2005. PMID: 16334131
Cited by
-
Medical management of brain metastases.Neurooncol Adv. 2020 Aug 9;2(1):vdaa015. doi: 10.1093/noajnl/vdaa015. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 32793881 Free PMC article. Review.
-
A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.Wellcome Open Res. 2019 Jan 22;4:8. doi: 10.12688/wellcomeopenres.15010.1. eCollection 2019. Wellcome Open Res. 2019. PMID: 30801037 Free PMC article.
-
An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.Elife. 2021 Sep 28;10:e68929. doi: 10.7554/eLife.68929. Elife. 2021. PMID: 34581270 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.Clin Pharmacokinet. 1992 May;22(5):327-58. doi: 10.2165/00003088-199222050-00002. Clin Pharmacokinet. 1992. PMID: 1505141 Review.
-
A Need for More Molecular Profiling in Brain Metastases.Front Oncol. 2022 Jan 25;11:785064. doi: 10.3389/fonc.2021.785064. eCollection 2021. Front Oncol. 2022. PMID: 35145903 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical